Study of Rituximab and Brentuximab Vedotin for Relapsed Classical Hodgkin Lymphoma

PHASE1TerminatedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

July 31, 2017

Study Completion Date

July 31, 2017

Conditions
Lymphoma
Interventions
BIOLOGICAL

Brentuximab vedotin

Day 1 every three weeks (weeks 0, 3, 6, 9, ... 27): 1.8 mg/kg IV. Ten doses maximum.

BIOLOGICAL

Rituximab

Day 1 of weeks 12, 13, 14, 15, 18, 21, 24, and 27: 375 mg/m\^2 IV. Additional doses are given at three and six months post week 27.

Trial Locations (1)

21287

The Sidney Kimmel Comprehensive Canceer Center, Baltimore

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER

NCT01900496 - Study of Rituximab and Brentuximab Vedotin for Relapsed Classical Hodgkin Lymphoma | Biotech Hunter | Biotech Hunter